ID

11850

Beschreibung

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology; ODM derived from: https://clinicaltrials.gov/show/NCT02140736

Link

https://clinicaltrials.gov/show/NCT02140736

Stichworte

Versionen (1)
  1. 10.08.15 10.08.15 - Julian Varghese
Hochgeladen am

10. August 2015

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

Englisch

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

patients of more than 18 years of age
Beschreibung

patients of more than 18 years of age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
patients presenting with anemia following chemotherapy
Beschreibung

patients presenting with anemia following chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C0002871
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
Beschreibung

patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0280100
UMLS CUI [2]
C3665472
UMLS CUI [3]
C0376545
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
Beschreibung

- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)

Datentyp

boolean

patients eligible for epoetin alfa biosimilar treatment
Beschreibung

patients eligible for epoetin alfa biosimilar treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013893
UMLS CUI [1,2]
C0357126
Exclusion Criteria
Beschreibung

Exclusion Criteria

patients are not receiving chemotherapy
Beschreibung

patients are not receiving chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C3665472
patients already included in an epoetin zeta trial
Beschreibung

patients already included in an epoetin zeta trial

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2242969
UMLS CUI [1,2]
C1997870
patients presenting with a contraindication to epoetin zeta
Beschreibung

patients presenting with a contraindication to epoetin zeta

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1997870
patients presenting with hypersensitivity to the active principle or any of the excipients
Beschreibung

patients presenting with hypersensitivity to the active principle or any of the excipients

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0014822
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
Beschreibung

patient with erythroblastopenia or acquired pure red cell aplasia (aprca)

Datentyp

boolean

Alias
UMLS CUI [1]
C0877221
UMLS CUI [2]
C0340961
patient with uncontrollable arterial hypertension
Beschreibung

patient with uncontrollable arterial hypertension

Datentyp

boolean

Alias
UMLS CUI [1]
C1868885
patients who cannot receive adequate prophylaxis by antithrombotic agents
Beschreibung

patients who cannot receive adequate prophylaxis by antithrombotic agents

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1704311
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
age
Item
patients of more than 18 years of age
boolean
C0001779 (UMLS CUI [1])
Chemotherapy | Anemia | Hematologic Neoplasms
Item
patients presenting with anemia following chemotherapy
boolean
C3665472 (UMLS CUI [1])
C0002871 (UMLS CUI [2])
Solid tumour | Chemotherapy | Hematologic Neoplasms
Item
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
boolean
C0280100 (UMLS CUI [1])
C3665472 (UMLS CUI [2])
C0376545 (UMLS CUI [3])
patient inclusion regardless of chemotherapy
Item
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
boolean
Eligibility Determination; Epoetin Alfa
Item
patients eligible for epoetin alfa biosimilar treatment
boolean
C0013893 (UMLS CUI [1,1])
C0357126 (UMLS CUI [1,2])
Chemotherapy
Item
patients are not receiving chemotherapy
boolean
C3665472 (UMLS CUI [1])
clinical trial participant (history); epoetin zeta
Item
patients already included in an epoetin zeta trial
boolean
C2242969 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Contraindication; epoetin zeta
Item
patients presenting with a contraindication to epoetin zeta
boolean
C0522473 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Hypersensitivity; Erythropoietin
Item
patients presenting with hypersensitivity to the active principle or any of the excipients
boolean
C0020517 (UMLS CUI [1,1])
C0014822 (UMLS CUI [1,2])
Decreased erythroid precursor production | Acquired red cell aplasia
Item
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
boolean
C0877221 (UMLS CUI [1])
C0340961 (UMLS CUI [2])
Uncontrolled hypertension
Item
patient with uncontrollable arterial hypertension
boolean
C1868885 (UMLS CUI [1])
Contraindication; Antithrombotic Agents
Item
patients who cannot receive adequate prophylaxis by antithrombotic agents
boolean
C0522473 (UMLS CUI [1,1])
C1704311 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video